Resverlogix Corp
TSX:RVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Resverlogix Corp
Selling, General & Administrative
Resverlogix Corp
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Resverlogix Corp
TSX:RVX
|
Selling, General & Administrative
-$1.9m
|
CAGR 3-Years
35%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Selling, General & Administrative
-CA$2.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Selling, General & Administrative
-$101.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-32%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Selling, General & Administrative
-$79.6m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-23%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Selling, General & Administrative
-CA$17.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-69%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Selling, General & Administrative
-$28.7m
|
CAGR 3-Years
-93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Resverlogix Corp
Glance View
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.
See Also
What is Resverlogix Corp's Selling, General & Administrative?
Selling, General & Administrative
-1.9m
USD
Based on the financial report for Dec 31, 2025, Resverlogix Corp's Selling, General & Administrative amounts to -1.9m USD.
What is Resverlogix Corp's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
19%
Over the last year, the Selling, General & Administrative growth was -9%. The average annual Selling, General & Administrative growth rates for Resverlogix Corp have been 35% over the past three years , 19% over the past five years .
